AXTLE Drug Patent Profile
✉ Email this page to a colleague
When do Axtle patents expire, and when can generic versions of Axtle launch?
Axtle is a drug marketed by Avyxa Holdings and is included in one NDA.
The generic ingredient in AXTLE is pemetrexed dipotassium. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the pemetrexed dipotassium profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AXTLE?
- What are the global sales for AXTLE?
- What is Average Wholesale Price for AXTLE?
Summary for AXTLE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 3,803 |
| What excipients (inactive ingredients) are in AXTLE? | AXTLE excipients list |
| DailyMed Link: | AXTLE at DailyMed |
Pharmacology for AXTLE
| Drug Class | Folate Analog Metabolic Inhibitor |
| Mechanism of Action | Folic Acid Metabolism Inhibitors |
US Patents and Regulatory Information for AXTLE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avyxa Holdings | AXTLE | pemetrexed dipotassium | POWDER;INTRAVENOUS | 210661-001 | Jun 28, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Avyxa Holdings | AXTLE | pemetrexed dipotassium | POWDER;INTRAVENOUS | 210661-002 | Jun 28, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
